{
    "name": "Gaucher Disease",
    "slug": "gaucher-disease",
    "aliases": ["Gaucher's Disease", "Glucocerebrosidase Deficiency", "GD"],
    "description": "Gaucher disease is an inherited metabolic disorder caused by a deficiency of the enzyme glucocerebrosidase. This leads to accumulation of fatty substances in cells and organs, particularly the spleen, liver, and bone marrow.",
    "category": "METABOLIC",
    "icdCode": "E75.22",
    "orphaCode": "ORPHA355",
    "omimCode": "230800",
    "prevalence": "1 in 40,000 to 60,000 (1 in 450 Ashkenazi Jewish)",
    "estimatedCases": 10000,
    "ageOfOnset": "Type 1: Childhood to adulthood; Type 2: Infancy; Type 3: Childhood",
    "inheritance": "AUTOSOMAL_RECESSIVE",
    "symptoms": [
        "Enlarged spleen (splenomegaly)",
        "Enlarged liver (hepatomegaly)",
        "Bone pain and fractures",
        "Easy bruising",
        "Fatigue",
        "Anemia",
        "Low platelet count",
        "Delayed growth in children",
        "Neurological symptoms (Type 2 and 3)"
    ],
    "affectedSystems": [
        "Hematological system",
        "Skeletal system",
        "Hepatic system",
        "Spleen",
        "Central nervous system (Types 2 and 3)"
    ],
    "prognosis": "Type 1: Normal lifespan with treatment; Type 2: Death in infancy; Type 3: Variable",
    "lifeExpectancy": "Type 1: Near-normal with treatment; Type 2: 1-2 years; Type 3: Variable",
    "diagnosticMethods": [
        "Enzyme activity assay (glucocerebrosidase)",
        "Genetic testing for GBA mutations",
        "Bone marrow biopsy showing Gaucher cells",
        "Complete blood count",
        "MRI for bone involvement",
        "Liver/spleen volume measurement"
    ],
    "treatmentOptions": [
        {
            "name": "Imiglucerase (Cerezyme)",
            "type": "MEDICATION",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": 1994
        },
        {
            "name": "Velaglucerase alfa (VPRIV)",
            "type": "MEDICATION",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": 2010
        },
        {
            "name": "Taliglucerase alfa (Elelyso)",
            "type": "MEDICATION",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": 2012
        },
        {
            "name": "Eliglustat (Cerdelga)",
            "type": "MEDICATION",
            "effectiveness": "HIGHLY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": 2014
        },
        {
            "name": "Miglustat (Zavesca)",
            "type": "MEDICATION",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": 2003
        },
        {
            "name": "Bone marrow transplant",
            "type": "TRANSPLANT",
            "effectiveness": "CURATIVE",
            "fdaApproved": true,
            "approvalYear": null
        }
    ],
    "researchStatus": "ACTIVE_TRIALS",
    "clinicalTrialsCount": 52,
    "keyResearchCenters": [
        "NIH Clinical Center",
        "Yale Gaucher Program",
        "Royal Free Hospital London",
        "Shaare Zedek Medical Center Jerusalem",
        "Universit√§tsklinikum Mainz"
    ],
    "patientOrganizations": [
        {
            "name": "National Gaucher Foundation",
            "url": "https://www.gaucherdisease.org",
            "country": "USA"
        },
        {
            "name": "Gaucher's Association UK",
            "url": "https://www.gaucher.org.uk",
            "country": "UK"
        },
        {
            "name": "European Gaucher Alliance",
            "url": "https://www.eurogaucher.org",
            "country": "Europe"
        }
    ],
    "relatedConditions": [
        "Niemann-Pick disease",
        "Fabry disease",
        "Tay-Sachs disease",
        "Other lysosomal storage disorders",
        "Parkinson's disease (GBA mutations are a risk factor)"
    ],
    "specialistTypes": [
        "Hematologist",
        "Geneticist",
        "Metabolic Disease Specialist",
        "Orthopedic Surgeon",
        "Neurologist (Types 2 and 3)"
    ],
    "eli5Summary": "Gaucher disease happens when the body can't properly clean up certain fats inside cells. These fats pile up and make the liver and spleen grow too big, and can make bones weak. Doctors can give special medicines that help the body clean up these fats.",
    "clinicalSummary": "Gaucher disease is an autosomal recessive lysosomal storage disorder caused by mutations in the GBA gene encoding glucocerebrosidase. Three clinical types are recognized: Type 1 (non-neuronopathic, most common), Type 2 (acute neuronopathic), and Type 3 (chronic neuronopathic). Pathognomonic Gaucher cells accumulate in the reticuloendothelial system. First-line treatment is enzyme replacement therapy (ERT) or substrate reduction therapy (SRT). Notably, GBA mutations are the most common genetic risk factor for Parkinson's disease.",
    "historicalBackground": "Philippe Gaucher first described the disease in 1882. The enzymatic defect was identified in 1965 by Roscoe Brady at NIH. The development of enzyme replacement therapy by Brady's team in the 1990s revolutionized treatment and served as a model for treating other lysosomal storage disorders.",
    "recentBreakthroughs": [
        {
            "year": 2024,
            "title": "Gene therapy clinical trials advance",
            "description": "AAV-based gene therapy trials show sustained enzyme production and potential for one-time treatment.",
            "sourceUrl": null
        },
        {
            "year": 2023,
            "title": "New substrate reduction therapies",
            "description": "Next-generation SRT drugs with improved brain penetration show promise for neuronopathic forms.",
            "sourceUrl": null
        },
        {
            "year": 2022,
            "title": "Parkinson's disease connection clarified",
            "description": "Research reveals molecular mechanisms linking GBA mutations to Parkinson's pathology.",
            "sourceUrl": null
        }
    ],
    "heroImage": null,
    "diagrams": [],
    "lastUpdated": "2024-12-01",
    "reviewedBy": "MDRPedia Medical Team",
    "sources": [
        {
            "name": "OMIM - Gaucher Disease Type 1",
            "url": "https://www.omim.org/entry/230800"
        },
        {
            "name": "GeneReviews - Gaucher Disease",
            "url": "https://www.ncbi.nlm.nih.gov/books/NBK1269/"
        }
    ]
}
